CaptureSelect™ Human Fab-kappa Kinetics Biotin Conjugate is a bi-functional ligand construct consisting of 2 different 13 kDa recombinant single domain antibody fragments (affinity ligands). The CaptureSelect™ anti-LC-kappa (Hu) ligand that specifically binds to the constant domain of human kappa light chains is genetically fused to the CaptureSelect™ anti-IgG-CH1 ligand that specifically binds to the CH1 domain of all four human IgG subclasses. The bi-functional affinity ligand is chemically conjugated to biotin via an appropriate spacer that retains the binding reactivity of the ligand when used in combination with streptavidin-based conjugates or streptavidin pre-coated surfaces.
The CaptureSelect™ Human Fab-kappa Kinetics Biotin Conjugate allows you to:
• Screen Fab-antigen interactions—the Human Fab-kappa Kinetics Biotin Conjugate allows high affinity capture of human IgG Fab fragments that possess a kappa light chain. Extreme low off-rates [k(diss)] are achieved through avidity by targeting the CL-kappa domain of the Fab (light chain) and its IgG CH1 domain (heavy chain) simultaneously, thereby enabling Fab screening on target binding kinetics.
Applications for CaptureSelect™ Human Fab-kappa Kinetics Biotin Conjugate include ELISA, Western blot, Gyrolab™-based immunoassays, and label-free detection platforms such as those based on surface plasmon resonance (Biacore™ and IBIS-MX96 systems) and bio-layer interferometry (ForteBio™ Octet™ systems).
Animal origin statement
CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12–15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).